Author’s reply to ‘bone metastasis of limb segments: is mesometastasis another poor prognostic factor of cancer patients?’

2020 ◽  
Vol 50 (10) ◽  
pp. 1226-1226
Author(s):  
Shoichiro Tani ◽  
Yutaka Morizaki ◽  
Kosuke Uehara ◽  
Ryoko Sawada ◽  
Hiroshi Kobayashi ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Poor Prognostic Factor

scholarly journals Bone metastasis of limb segments: Is mesometastasis another poor prognostic factor of cancer patients?

2020 ◽  
Vol 50 (6) ◽  
pp. 688-692
Author(s):  
Shoichiro Tani ◽  
Yutaka Morizaki ◽  
Kosuke Uehara ◽  
Ryoko Sawada ◽  
Hiroshi Kobayashi ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Prognostic Factor ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Survival Curve ◽  
Lower Leg ◽  
Poor Prognostic Factor ◽  
Significant Difference ◽  
The University ◽  
Distal Site

Abstract Objective In contrast to acrometastasis, defined as bone metastasis to the hand or foot, the frequency and prognosis of bone metastasis of other limb segments remain unclear. To compare prognosis according to sites of bone metastasis, we defined two new terms in this study: ‘mesometastasis’ and ‘rhizometastasis’ as bone metastasis of ‘forearm or lower leg’ and ‘arm or thigh’, respectively. Methods A total of 539 patients who were registered to the bone metastasis database of The University of Tokyo Hospital from April 2012 to May 2016 were retrospectively surveyed. All patients who were diagnosed to have bone metastases in our hospital are registered to the database. Patients were categorized into four groups according to the most distal site of bone metastases: ‘acrometastasis’, ‘mesometastasis’, ‘rhizometastasis’ and ‘body trunk metastasis’. Results The frequency of rhizometastasis (22.5%) or body trunk metastasis (73.1%) was significantly higher than that of acrometastasis (2.0%) or mesometastasis (2.4%). The median survival time after diagnosis of bone metastases for each group was as follows: 6.5 months in acrometastasis, 4.0 months in mesometastasis, 16 months in rhizometastasis, 17 months in body trunk metastasis and 16 months overall. In survival curve, there was a statistically significant difference between mesometastasis and body trunk metastasis. Conclusions Our findings suggest that ‘mesometastasis’ could be another poor prognostic factor in cancer patients and that patients with mesometastasis should receive appropriate treatments according to their expected prognosis.

scholarly journals Bone Scan Index Is a Prognostic Factor for Breast Cancer Patients with Bone Metastasis Being Treated with Zoledronic Acid

2015 ◽  
Vol 05 (03) ◽  
pp. 149-158
Author(s):  
Yukinori Okada ◽  
Tatsuyuki Abe ◽  
Yasuo Nakajima ◽  
Itsuko Okuda ◽  
Brandon D. Lohman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Metastasis ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Bone Scan ◽  
Breast Cancer Patients ◽  
Bone Scan Index

scholarly journals Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients

2020 ◽  
Vol 38 (10) ◽  
pp. 993-996
Author(s):  
Toyokazu Hayakawa ◽  
Ken-ichi Tabata ◽  
Hideyasu Tsumura ◽  
Shogo Kawakami ◽  
Takeo Katakura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Pelvic Bone ◽  
Significant Prognostic Factor

scholarly journals Acute Organ Failure and Risk of Admission to Intensive Medical Care in Cancer Patients, A Single Centre Inception Cohort Study

2021 ◽  
Author(s):  
Sara Coelho ◽  
Teresa Ribeiro ◽  
Isabel Pereira ◽  
Delfim Duarte ◽  
Ana Afonso ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prognostic Factor ◽  
Hospital Stay ◽  
Cancer Patients ◽  
Prospective Cohort ◽  
Inpatient Care ◽  
Cumulative Risk ◽  
Single Centre ◽  
Poor Prognostic Factor ◽  
Icu Admission

Abstract Background: Risk of acute organ failure (AOF) in cancer patients on systemic antineoplastic treatment is unknown. However, up to 5% of non-hematologic and 15% of hematologic cancer patients will need to be admitted to an intensive care unit (ICU). IPOPSCI-2017/01 is a prospective cohort study designed to ascertain the cumulative incidence of AOF and ICU admission in adult cancer patients. Methods: Single centre prospective cohort study with consecutive sampling of adult cancer patients admitted for unscheduled inpatient care while on, or up to 8 weeks after, systemic cancer treatment. Primary endpoints were cumulative risk of developing AOF and of ICU admission. Six months accrual expected an accrual of 400 patients to infer a population risk of ICU admission with a precision error of 2% and type 1 error of 5%. Results: Between August 2018 and February 2019, 10392 patients were on systemic anti-neoplastic treatment, 358 had unscheduled inpatient care and were eligible for inclusion and 285 were included. Mean age was 60.9 years-old, 50.9% were male, 52.3% had adjusted Charlson Comorbidity Index ≥3 and hematologic cancers accounted for 17.9% of patients. The cumulative risk of AOF on hospital admission was 29.5% (95%CI: 26-33) and during hospital stay was 39.6% (95%CI: 35-44). Cumulative risk of ICU admission of the patients with AOF was 15.0% (95%CI: 12-18) and if artificial life support criteria and AOF, cumulative risk of ICU admission was 31.5% (95%CI:CI: 23-40). On admission, 62.1% of patients were considered not eligible for artificial organ replacement therapy (no-AORT) and 34.3% of patients who developed AOF while in-hospital were judged no-AORT. Overall, 17 (15%) patients with AOF were admitted to ICU, 31.5% for AORT. Median follow up was 9.5 months. Inpatient mortality was 17.5%, with ICU mortality rate of 58.8%, with median cohort survival 134 days (95%CI: 106-162). On multivariate analysis, AOF was an independent poor prognostic factor (HR 1.6; 95%CI: 1.2-2.2). Conclusions: Risk of AOF in cancer patients admitted for unscheduled inpatient care while on systemic treatment is 39.6%, and risk of ICU admission is 15.0%. AOF in cancer patients was an independent poor prognostic factor for inpatient hospital stay and 6-months survival.

Sign in / Sign up

Export Citation Format

Share Document